Nucl Med Biol 2020 May - Jun;84-85:46-54. Epub 2020 Feb 3.
Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada; Department of Medical Imaging, University of Toronto, Toronto, ON, Canada; Toronto General Research Institute, Joint Department of Medical Imaging, University Health Network, Toronto, ON, Canada. Electronic address:
Introduction: Our objective was to determine the feasibility of extending our previously reported PET imaging study of pancreatic cancer (PnCa) with [Cu]Cu-NOTA-panitumumab F(ab') to radioimmunotherapy (RIT) by exploiting the β-particle and Auger electron emissions of Cu (PET theranostic concept). To enhance the effectiveness of [Cu]Cu-NOTA-panitumumab F(ab'), we further combined RIT with radiosensitizing gemcitabine (GEM) and the poly(ADP)ribose polymerase inhibitor (PARPi), rucaparib.
Methods: Normal tissue toxicity was assessed in non-tumor-bearing NOD-scid mice injected i. Read More